Ira Mellman, departing Genentech VP, cancer immunology
August 15, 2024 05:55 PM EDTUpdated August 16, 06:26 AM
People
Pharma

Genen­tech dis­solves can­cer im­munol­o­gy group, and re­search ex­ec­u­tive Ira Mell­man will leave com­pa­ny

Lei Lei Wu

News Reporter

Genen­tech is dis­man­tling its can­cer im­munol­o­gy team in a re­or­ga­ni­za­tion of its work in the field, and its VP of can­cer im­munol­o­gy, Ira Mell­man, will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA is poised to pull Ocali­va as ad­comm doc­u­ments ques­tion post-ap­proval study re­sults

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

Roche says its Car­mot-ac­quired obe­si­ty pill is ef­fec­tive in ear­ly study

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

CVS says it won't cor­rect con­gres­sion­al tes­ti­mo­ny

No­vo Nordisk's long­stand­ing GLP-1 re­duced BMI by 7% in chil­dren in Phase 3 tri­al

A service from the Financial Times